Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- November 1, 2022
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Androgen Antagonists (MeSH)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- Docetaxel (MeSH)
- Hormones (MeSH)
- Humans (MeSH)
- Male (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
- Prostatic Neoplasms (MeSH)
published in
- Journal of Clinical Oncology Journal